Greater Understanding of Cell & Gene Therapies Supports Plan Coverage

Naga Vivekanandan explores the rapid advancement of cell and gene therapies and the implications for self-funded health plans. She discusses the clinical promise and high-cost realities of these treatments, highlighting how thoughtful coverage strategies, clinical evaluation, and cost-containment tools can help plan sponsors balance innovation with fiscal responsibility.